Prevention of fungal infections in hematology patients

Infection Control and Hospital Epidemiology

Volumn 17, Issue 8, 1996, Pages 545-551

  Philpott Howard, John ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMATOLOGIC DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; INFECTION CONTROL; MICROBIOLOGY; MYCOSIS; OPPORTUNISTIC INFECTION; REVIEW; RISK FACTOR;

HEMATOLOGIC DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION CONTROL; MYCOSES; OPPORTUNISTIC INFECTIONS; RISK FACTORS;

EID: 0030204148     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.2307/30141290     Document Type: Article

References (68)

1. Schimpff SC. Infections in the cancer patient - diagnosis, prevention and treatment. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1994:2666-2674.
2. Morrison VA, Haake RJ, Weisdorf DJ. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994;96:497-503.
3. Chandrasekar PH, Weinmann A, Shearer C, Bone Marrow Transplant Team. Autopsy-identified infections among bone marrow transplant recipients: a clinicopathologic study of 56 patients. Bone Marrow Transplant 1995;16:675-681.
4. Rosetti F, Brawner DL, Bowden R, et al. Fungal liver infection in marrow transplant recipients: prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis 1995;20:801-811.
5. Walsh TJ, Hiemenez J, Pizzo PA. Editorial response: evolving risk factors for invasive fungal infections - all neutropenic patients are not the same. Clin Infect Dis 1994;18:793-798.
6. Wiley JM, Smith N, Leventhal BG, et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990;8:280-286.
7. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-2508.
8. Bochud P-Y, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994;18:25-31.
9. O'Donnell MR, Schmidt GM, Tegtmeir BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin in high-risk patients. J Clin Oncol 1994;12:827-834.
10. Barnes RA. Immunotherapy and immunoprophylaxis in bone marrow transplantation. J Hosp Infect 1995;30(suppl):223-231.
11. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 1992;10:267-272.
12. Nucci M, Schlechter M, Spector N, et al. Antibiotic regimen as an independent risk factor for disseminated fungal infections in neutropenic patients in Brazil. Trans R Soc Trop Med Hyg 1995;89:107-110.
13. Karabinis A, Hill C, Leclercq B, Tancrede C, Baume D, Andremont A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988;26:429-432.
14. McNeil MM. Candida. In: Mayhall CG, ed. Hospital Epidemiology and Infection Control. Baltimore, MD: Williams & Wilkins; 1996:408-419.
15. Reagan DR, Pfaller MA, Hollis RJ, Huston B, Wenzel RP. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol 1990;28:2733-2738.
16. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital acquired candidemia: attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-2645.
17. Bross J, Talbot GH, Maislin G, Jurwitz S, Stron BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989;87:614-620.
18. Bodey GP, Rosenbaum B. Effect of prophylactic measures on the microbial flora of patients in protected environment units. Medicine 1974;53:209-228.
19. DeGregorio MW, Lee WMF, Ries CA. Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1982;50:2780-2784.
20. Buchanan AG, Riben PD, Rayner EN, Parker SE, Ronald AR, Louie TJ. Nystatin prophylaxis of fungal colonization and clinical outcome. Clin Invest Med 1985;8:139-147.
21. Philpott-Howard J, Wade J, Mufti G, Brammer K, Ehninger G. Randomized comparison of oral fluconazole vs. oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother 1993;31:973-984.
22. Flynn PM, Cunningham CK, Kerkering T, et al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. J Pediatr 1995;127:322-328.
23. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-851.
24. Bills ME, Clink H, Ernst P, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with hematological malignancies and bone marrow transplants. Eur J Clin Microbiol Infect Dis 1994;13:3-11.
25. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
26. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation. A prospective, randomized, double blind study. J Infect Dis 1995;171:1545-1552.
27. O'Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994;12:827-834.
28. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995;172:1035-1041.
29. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
30. Pfaller MA. Epidemiology of candidiasis. J Hosp Infect 1995;30(suppl):329-338.
31. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infections among patients with bone marrow transplant and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-1277.
32. Stewart A, Powles R, Hewetson M, Antrum J, Richardson C, Mehta J. Costs of antifungal prophylaxis after bone marrow transplantation. Pharmaco Economics 1995;8:350-361.
33. Grant SM, Clissold SP. Itraconazole. A review of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-344.
34. Walsh TJ, Lee JW. Prevention of invasive fungal infections in patients with neoplastic disease. Clin Infect Dis 1993;17(suppl 2):468S-480S.
35. Winston DJ. Prophylaxis and treatment of infection in the bone marrow transplant recipient. Curr Clin Top Infect Dis 1993;13:293-321.
36. Vreugdenhil G, Van-Dijke BJ, Donnelly JP. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993;11:353-358.
37. Working Party of the British Society of Antimicrobial Chemotherapy. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. J Antimicrob Chemother 1993;32:5-21.
38. Dankner WM, Spector SA, Fierer J, et al. Malassezia fungemia in neonates and adults: complication of hyperalimentation. Rev Infect Dis 1987;9:743-753.
39. Garaventa A, Rondelli R, Castagnola E, et al for the Italian Association of Pediatric Hematology-Oncology BMT Group. Fatal pneumopathy in children after bone marrow transplantation - report from the Italian Registry. Bone Marrow Transplant 1995;16:669-674.
40. Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Ann Intern Med 1996;156:177-188.
41. Burnie JP. Candida and hands. J Hosp Infect 1986;8:14.
42. van Belkum A, Melchers W, de Pauw BE, Scherer S, Quint W, Meis J. Genotypic characterization of sequential Candida albicans isolates from fluconazole-treated neutropenic patients. J Infect Dis 1994;169:1062-1070.
43. Weems JJ Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992;14:756-766.
44. Strausbaugh LJ, Sewell DL, Ward TT, Pfaller MA, Heitzman T, Tjoelker R. High frequency of yeast carriage on hands of hospital personnel. J Clin Microbiol 1994;32:2299-2300.
45. Darbord JC, Vincent F, Boutron L, Goury V, Guyomard S. Susceptibility of Torulopsis glabrata in the presence of six antifungal agents determined by comparison of growth at several pHs. Appl Environ Microbiol 1987;53:593-595.
46. Scott EM, Gorman SP, McGrath SJ. An assessment of the fungicidal activity of antimicrobial agents used for hard-surface and skin disinfection. J Clin Hosp Pharm 1986;11:199-205.
47. Hay RJ, Clayton YM, Goodley JM. Fungal aerobiology: how, when, and where? J Hosp Infect 1995;30(suppl):352-357.
48. Arnow PM, Sadigh M, Costas C, et al. Endemic and epidemic aspergillosis associated with in-hospital replication of Aspergillus organisms. J Infect Dis 1991;164:998-1002.
49. Sheretz RJ, Belani A, Kamer BS, et al. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 1987;83:709-718.
50. Barnes RA, Rogers TR. Control of an outbreak of nosocomial aspergillosis by laminar air-flow isolation. J Hosp Infect 1989;14:89-94.
51. Pannuti CS. Hospital environment for high-risk patients. In: Wenzel RP, ed. Prevention and Control of Nosocomial Infection. 2nd ed. Baltimore, MD: Williams & Wilkins; 1993:365-384.
52. Fenelon LE. Protective isolation: who needs it? J Hosp Infect 1995;30(suppl):218-222.
53. Philpott-Howard JN, Casewell MW. Hospital Infection Control: Policies and Practical Procedures. London, UK: WB Saunders; 1994:81-84.
54. De-Bock R, Gyssens I, Peetermans M, Nolard N. Aspergillus in pepper. Lancet 1989;ii:331-332.
55. Vargas S, Hughes WT, Giannini MA. Aspergillus in pepper. Lancet 1990;336:881.
56. Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994;97:509-514.
57. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia: fluconazole versus intravenous amphotericin B. Cancer 1994;73:2099-2106.
58. Jeffery GM, Beard ME, Ikram RB. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991;90:685-692.
59. Graybill JR, Najvar LK, Holmberg JD, Luther MF. Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice. Antimicrob Agents Chemother 1995;39:924-929.
60. Wardle HM, Law D, Moore CB, Mason C, Denning DW. In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida species. Antimicrob Agents Chemother 1995;39:868-871.
61. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Ann Rev Microbiol 1994;48:471-497.
62. Martino P, Raccah R, Gentile G, Venditti M, Girmenia C, Mandelli F. Aspergillus colonization of the nose and pulmonary aspergillosis in neutropenic patients: a retrospective study. Haematologica 1989;74:263-265.
63. Riley DK, Pavia AT, Beatty PG, Denton D, Carroll KC. Surveillance cultures in bone marrow transplant recipients: worthwhile or wasteful? Bone Marrow Transplant 1995;15:469-473.
64. Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, Lillich TT. Control of oral mucositis and candidiasis in marrow transplantation: a prospective double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 1988;3:483-493.
65. McWhinney PH, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993;17:397404.
66. Tavares D, Ferreira P, Vilanova M, Videira A, Arala-Chaves M. Immunoprotection against systemic candidiasis in mice. Int Immunol 1995;7:785-796.
67. Han Y, Cutler JE. Antibody response that protects against disseminated candidiasis. Infect Immun 1995;63:2714-2719.
68. Polonelli L, Poulain D, Cole GT. New strategies in vaccination against fungal infections. J Med Vet Mycol 1994;32(suppl 1):105-112.